Abstract 481P
Background
Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small cell lung cancer (NSCLC). Here, we elucidate the feasibility of CGP in early-stage NSCLC, and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms.
Methods
Surgically resected NSCLC samples (N=96) collected between October 2011 and April 2020 at Yonsei Cancer Center were analyzed using whole-exome sequencing (WES) (Illumina DRAGEN, v3.8) (N=96), TruSight Oncology 500 (TSO500, v2.0) (for research use only) (Illumina) (N=96), and Foundation One CDx Assay (F1CDx) (N=26) to assess the concordance in TMB calculation and targetable mutations. Programmed death-ligand 1 (PD-L1) expression were evaluated using Vectra Polaris (Akoya).
Results
The stage distribution after surgery was 80% I (N=77) and 20% II (N=19). Ninety-nine percent (N=95) were adenocarcinoma. All 96 samples were analyzed with WES and TSO500. Among these samples, 26 samples were analyzed with F1CDx. The median TMB with WES and TSO500 was 1.57 and 4.7 mut/Mb, respectively (p<0.05). The median TMB was 1.88, 5.5, 4 mut/Mb for WES, TSO500 and F1CDx, respectively (p=0.0048). Linear regression analysis of TMB values calculated using concordance correlation coefficient (CCC) between WES and TSO500 resulted in a R2=0.76. For PD-L1 tumor proportion score (TPS) of <1% (negative, N=18), ≥1% (low, N=68) and ≥ 50% (high, N=10), the CCC were 0.075, 0.79, and 0.95, respectively. The CCC values for TMB concordance were variable between 3 platforms (WES vs. TSO500, R2=0.87; WES v. F1CDx, R2=0.72; TSO500 vs. F1CDx, R2=0.84). Mutation landscape revealed EGFR mutation (51%, N=49) as the most common actionable driver mutation, comprising of L858R (N=22), E19del (N=20), and other non-common EGFR mutations (N=7).
Conclusions
F1CDx and TSO500 showed robust analytical performance for TMB assessment with TSO500 showing stronger concordance of TMB with high PD-L1 expression. As paradigm for early-resected NSCLC continues to evolve, understanding TMB and mutation landscape may help advance clinical outcomes for this subset of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yonsei Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract